8.3 Hepatobiliary Disorders: MASLD/MASH, Viral & Alcoholic Hepatitis, Cirrhosis & Cholelithiasis
Key Takeaways
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD, formerly NAFLD) requires hepatic steatosis plus at least one cardiometabolic risk factor; risk stratification utilizes the non-invasive FIB-4 Index (Age, AST, ALT, Platelets) where FIB-4 <1.30 (<2.0 in age ≥65) indicates low risk for advanced fibrosis, while >2.67 mandates hepatology referral for advanced fibrosis/cirrhosis.
- In viral hepatitis serology: Hepatitis A acute infection is diagnosed by Anti-HAV IgM; Hepatitis B chronic infection is defined by persistent HBsAg >6 months, while Anti-HBs alone indicates vaccine immunity and Anti-HBs + Anti-HBc Total indicates resolved natural infection; universal one-time Hepatitis C screening (Anti-HCV with reflex HCV RNA PCR) is recommended for all adults aged 18–79.
- Alcohol-associated liver disease classically exhibits an AST-to-ALT ratio ≥ 2:1 (with AST typically <300–500 U/L); in acute alcoholic hepatitis, a Maddrey's Discriminant Function (MDF) score ≥ 32 indicates severe disease with high short-term mortality benefiting from oral prednisolone.
- In cirrhosis with ascites, diagnostic paracentesis determines the Serum-Ascites Albumin Gradient (SAAG); a SAAG ≥ 1.1 g/dL confirms portal hypertension, managed by dietary sodium restriction (<2,000 mg/day) and dual diuretics (Spironolactone and Furosemide in a 100:40 mg ratio); Spontaneous Bacterial Peritonitis (SBP) is diagnosed by an ascitic fluid absolute neutrophil count (PMN) ≥ 250 cells/mm³, requiring immediate IV ceftriaxone and IV albumin.
- Right Upper Quadrant (RUQ) ultrasound is the initial imaging of choice for suspected biliary tract disease; acute cholecystitis presents with sustained RUQ pain, fever, leukocytosis, and a positive Murphy's sign, with HIDA cholescintigraphy serving as the most sensitive confirmatory test if ultrasound is equivocal.
Hepatobiliary Disorders: MASLD/MASH, Viral & Alcoholic Hepatitis, Cirrhosis & Cholelithiasis
Hepatobiliary pathology encompasses a vast spectrum of acute and chronic metabolic, infectious, toxic, and obstructive conditions. For the Adult-Gerontology Primary Care Nurse Practitioner (AGPCNP), board certification demands precision in interpreting liver chemistry panels, mastering viral hepatitis serologies, utilizing non-invasive fibrosis scoring tools, managing end-stage liver disease (ESLD) complications, and executing urgent decision-making for acute biliary emergencies.
1. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD / MASH)
Updated Multisociety Nomenclature (2023 Consensus)
In 2023, the international hepatology societies (AASLD, EASL, ALEH) updated the nomenclature to replace Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) to eliminate stigmatizing language and provide affirmative cardiometabolic diagnostic criteria.
+-----------------------------------------------------------------------------+
| MASLD / MASH PATHOPHYSIOLOGICAL SPECTRUM |
| |
| MASLD (Steatotic Liver Disease) |
| - Hepatic steatosis (>= 5% hepatocytes on histology or imaging) |
| - PLUS at least ONE of 5 Cardiometabolic Risk Factors: |
| 1. BMI >= 25 kg/m2 (>= 23 in Asian populations) or Waist Circ >94/80cm |
| 2. Fasting Glucose >= 100 mg/dL, 2-hr OGTT >= 140, or Type 2 Diabetes |
| 3. Blood Pressure >= 130/85 mmHg or on antihypertensive therapy |
| 4. Plasma Triglycerides >= 150 mg/dL or on lipid-lowering therapy |
| 5. Plasma HDL-C < 40 mg/dL (men) or < 50 mg/dL (women) |
| | |
| v |
| MASH (Metabolic Dysfunction-Associated Steatohepatitis) |
| - Steatosis PLUS hepatocyte ballooning injury and lobular inflammation |
| | |
| v |
| PROGRESSIVE FIBROSIS (Stages F0 to F4) -> CIRRHOSIS -> HEPATOCELLULAR CA |
+-----------------------------------------------------------------------------+
Primary Care Risk Stratification: The FIB-4 Algorithm
The primary care provider must distinguish simple steatosis (low risk) from progressive steatohepatitis with advanced bridging fibrosis (F3) or cirrhosis (F4). The Fibrosis-4 (FIB-4) Index is the guideline-endorsed first-line non-invasive screening tool:
FIB-4 Index Formula:
FIB-4 = (Age [years] × AST [U/L]) / (Platelet Count [10^9/L] × √ALT [U/L])
+-----------------------------------------------------------------------------+
| FIB-4 CLINICAL DECISION PATHWAY |
| |
| [PATIENT WITH MASLD] |
| | |
| v |
| [CALCULATE FIB-4 INDEX] |
| | |
| +-----------------------------+-----------------------------+ |
| | | |
| v v |
| [LOW RISK: FIB-4 < 1.30] [HIGH RISK: > 2.67]|
| (< 2.0 in age >= 65) - Advanced Fibrosis|
| - Advanced fibrosis excluded (>90% NPV) or Cirrhosis highly|
| - Primary care lifestyle management likely (>80% PPV)|
| - Repeat FIB-4 in 2 to 3 years - Immediate HEPATOLOGY|
| referral for care|
| | |
| v |
| [INDETERMINATE: FIB-4 1.30 - 2.67] |
| - Second-Line Testing: VIBRATION-CONTROLLED |
| TRANSIENT ELASTOGRAPHY (FibroScan / VCTE) |
| - Liver Stiffness < 8.0 kPa -> Low risk (PCP) |
| - Liver Stiffness >= 8.0 kPa -> Refer to Hepatology |
+-----------------------------------------------------------------------------+
Evidence-Based Management of MASLD / MASH
- Lifestyle & Weight Loss: 7% to 10% total body weight reduction achieves histological resolution of steatohepatitis and stabilizes or reverses hepatic fibrosis. Prescribe a Mediterranean diet and ≥ 150 min/week of moderate-intensity aerobic exercise.
- Cardiometabolic Pharmacotherapy:
- GLP-1 Receptor Agonists (e.g., Semaglutide, Liraglutide): Preferred for patients with concurrent Type 2 Diabetes or obesity; promotes weight loss and reduces steatohepatitis.
- Pioglitazone (30–45 mg daily): Improves liver histology in biopsy-proven MASH with or without diabetes (caution: fluid retention, heart failure, weight gain).
- Resmetirom (THR-beta agonist): First FDA-approved targeted agent for non-cirrhotic MASH with moderate-to-advanced liver fibrosis (F2–F3).
- Statin Therapy: Statins are safe and indicated in MASLD/MASH to reduce cardiovascular morbidity (the #1 cause of death in MASLD patients!). Statins are only contraindicated in acute decompensated liver failure.
2. Viral Hepatitis: Serology, Diagnostics & Management
+-----------------------------------------------------------------------------+
| HEPATITIS B SEROLOGY MASTER INTERPRETATION |
| |
| SEROLOGIC MARKER CLINICAL MEANING & SIGNIFICANCE |
| ----------------------------------------------------------------------- |
| HBsAg (Surface Ag) Indicates ACTIVE infection (acute or chronic). |
| Persisting > 6 months defines CHRONIC HBV. |
| |
| Anti-HBs (Surface Ab) Indicates IMMUNITY (from vaccine or cured natural).|
| Neutralizing protective antibody (> 10 mIU/mL). |
| |
| Anti-HBc IgM (Core Ab) Indicates ACUTE infection (< 6 months). Sole |
| marker positive during the "WINDOW PERIOD". |
| |
| Anti-HBc Total / IgG Indicates NATURAL EXPOSURE (past cured or chronic).|
| NEVER positive from vaccination alone! |
| |
| HBeAg (Envelope Ag) Indicates HIGH VIRAL REPLICATION & INFECTIVITY. |
| Anti-HBe (Envelope Ab) Indicates SEROCONVERSION (lower replication). |
| HBV DNA (PCR) Quantifies active viral load; guides antivirals. |
+-----------------------------------------------------------------------------+
Definitive HBV Serologic Diagnostic Profiles
| Clinical Diagnostic State | HBsAg | Anti-HBs | Anti-HBc IgM | Anti-HBc Total | HBeAg / HBV DNA |
|---|---|---|---|---|---|
| Susceptible (Never Exposed/Vaccinated) | Negative | Negative | Negative | Negative | Negative |
| Vaccine-Induced Immunity | Negative | POSITIVE | Negative | Negative | Negative |
| Natural Immunity (Resolved Past Infection) | Negative | POSITIVE | Negative | POSITIVE | Negative |
| Acute Hepatitis B Infection | POSITIVE | Negative | POSITIVE | POSITIVE | POSITIVE (High) |
| "Window Period" (Early Recovery) | Negative | Negative | POSITIVE | POSITIVE | Low / Undetectable |
| Chronic Hepatitis B (Active / Inactive) | POSITIVE | Negative | Negative | POSITIVE | Positive (Variable) |
Overview of Hepatitis A, C, D, and E
+-----------------------------------------------------------------------------+
| VIRAL HEPATITIS COMPARATIVE MATRIX |
| |
| VIRUS TRANSMISSION DIAGNOSTIC TEST CHRONICITY MANAGEMENT |
| ----------------------------------------------------------------------- |
| HAV Fecal-oral Acute: Anti-HAV IgM NO Supportive. |
| (food/water) Immune: Anti-HAV IgG (0%) Vaccine PEP |
| within 14 d. |
| |
| HBV Parenteral, HBsAg, Anti-HBc IgM, YES Entecavir or |
| Sexual, Perinatal HBV DNA PCR (5-10% adult Tenofovir if|
| >90% infant) active. |
| |
| HCV Parenteral Screen: Anti-HCV Ab YES Direct-Acting|
| (IV drug use, Confirmatory: HCV RNA (75-85%) Antivirals |
| transfusions) PCR (Quantitative) (DAAs, 8-12w)|
| >95% Cure! |
| |
| HDV Parenteral, Anti-HDV Ab, HDV RNA YES Requires HBV |
| Sexual (Requires HBsAg coat!) (Severe!) coat (HBsAg).|
| |
| HEV Fecal-oral Anti-HEV IgM, HEV RNA Rare (except Supportive. |
| (water, swine) transplant) High fatal in|
| pregnancy! |
+-----------------------------------------------------------------------------+
[!NOTE] Universal Hepatitis C Screening Mandate (USPSTF & CDC): All adults aged 18 to 79 years must receive a universal one-time screening for Hepatitis C virus using an Anti-HCV antibody test with reflex quantitative HCV RNA PCR. A positive antibody with positive HCV RNA confirms active viremia requiring 8 to 12 weeks of pangenotypic Direct-Acting Antiviral (DAA) therapy (e.g., Sofosbuvir-Velpatasvir or Glecaprevir-Pibrentasvir), achieving Sustained Virologic Response (SVR12 = microbiological cure) in > 95% to 98% of patients.
3. Alcohol-Associated Liver Disease & Acute Alcoholic Hepatitis
Pathophysiological Spectrum & Laboratory Hallmarks
Chronic excessive alcohol consumption (> 30 g/day in men, > 20 g/day in women) leads to steatosis, alcoholic steatohepatitis, progressive perivenular fibrosis, and micronodular cirrhosis.
+-----------------------------------------------------------------------------+
| ALCOHOL-ASSOCIATED HEPATITIS LAB PATTERN |
| |
| * AST to ALT Ratio >= 2:1 (Highly characteristic board hallmark!) |
| * AST and ALT levels are typically MODERATE (< 300 - 500 U/L) |
| (Transaminases > 1,000 U/L suggest viral, acetaminophen, or ischemic nec)|
| * Mechanism of AST > ALT: Pyridoxal-5'-phosphate (Vitamin B6) deficiency |
| depletes ALT synthesis; alcohol causes direct mitochondrial AST release.|
| * Markedly elevated Gamma-Glutamyl Transferase (GGT) |
| * Macrocytosis (MCV > 100 fL) independent of B12/folate |
| * Hyperbilirubinemia, elevated INR/PT, and leukocytosis (neutrophilia) |
+-----------------------------------------------------------------------------+
Severe Acute Alcoholic Hepatitis & Maddrey's Discriminant Function
Acute alcoholic hepatitis presents with acute-onset jaundice, fever, tender hepatomegaly, anorexia, ascites, and leukocytosis in a patient with heavy alcohol intake.
- Maddrey's Discriminant Function (MDF) Calculation:
MDF = 4.6 × [PT_patient - PT_control] (seconds) + Total Bilirubin (mg/dL) - Clinical Decision: An MDF ≥ 32 indicates severe alcoholic hepatitis with an estimated 30-day mortality of 30% to 50%. In the absence of active GI bleeding or systemic infection, initiate Prednisolone 40 mg daily for 28 days, followed by a taper (evaluated at Day 7 via the Lille Model to assess steroid responsiveness).
4. Cirrhosis & Complications of End-Stage Liver Disease (ESLD)
Cirrhosis is the irreversible, diffuse architectural distortion of the liver characterized by hepatic parenchymal necrosis, regenerative nodule formation, and dense bridging collagen deposition. It leads to portal hypertension (hepatic venous pressure gradient HVPG > 5 mmHg) and progressive liver synthetic failure.
+-----------------------------------------------------------------------------+
| PHYSICAL STIGMAS OF CIRRHOSIS |
| |
| [PORTAL HYPERTENSION] [HYPERESTROGENISM / SYNTHETIC FAILURE] |
| * Splenomegaly (leads to * Spider Angiomas (upper trunk/face) |
| thrombocytopenia < 150k) * Palmar Erythema (thenar/hypothenar) |
| * Ascites & Caput Medusae * Gynecomastia & Testicular Atrophy |
| * Gastroesophageal Varices * Loss of axillary / pubic body hair |
| * Internal Hemorrhoids * Terry's Nails (white proximal nailbed)|
| * Dupuytren's Contracture |
| [HEPATIC ENCEPHALOPATHY] * Coagulopathy (Elevated INR / PT) |
| * Asterixis ("Flapping Tremor") * Hypoalbuminemia & Peripheral Edema |
| * Inverted Sleep-Wake Cycle * Jaundice & Scleral Icterus |
+-----------------------------------------------------------------------------+
Major Complications of Cirrhosis & Clinical Management
+-----------------------------------------------------------------------------+
| CIRRHOSIS COMPLICATIONS & MANAGEMENT |
| |
| 1. ASCITES & SAAG CALCULATION |
| - Diagnostic Paracentesis: Calculate Serum-Ascites Albumin Gradient: |
| SAAG = Serum Albumin - Ascitic Fluid Albumin |
| * SAAG >= 1.1 g/dL: PORTAL HYPERTENSION (Cirrhosis, HF, Budd-Chiari) |
| * SAAG < 1.1 g/dL: NON-PORTAL HYPERTENSION (Peritoneal Carcinomatosis|
| Peritoneal TB, Pancreatitis, Nephrotic Syndrome) |
| - Medical Management: Dietary Sodium Restriction (< 2,000 mg/day). |
| - Dual Diuretics: SPIRONOLACTONE + FUROSEMIDE in a 100 mg : 40 mg |
| ratio (maintains normokalemia; titrate up to 400 mg : 160 mg). |
| - Large-Volume Paracentesis (> 5 L drained): Administer 25% IV ALBUMIN |
| at 6 to 8 grams per liter of fluid removed to prevent PICD. |
| |
| 2. SPONTANEOUS BACTERIAL PERITONITIS (SBP) |
| - Definition: Ascitic fluid infection without a surgical source. |
| - Diagnostic Criteria: Ascitic Absolute Neutrophil Count (PMN) >= 250 |
| cells/mm3 (PMN = Total Ascitic WBC x % Neutrophils). |
| - Empiric Treatment: IV CEFTRIAXONE (2g IV Q24H) x 5-7 days PLUS |
| IV ALBUMIN (1.5 g/kg within 6 hrs of dx, then 1.0 g/kg on Day 3) to |
| prevent Hepatorenal Syndrome and reduce mortality. |
| - Secondary Prophylaxis: Daily oral Ciprofloxacin or TMP-SMX for life. |
| |
| 3. GASTROESOPHAGEAL VARICES |
| - Primary Prophylaxis (medium/large varices or red wale marks): |
| NON-SELECTIVE BETA-BLOCKERS (Nadolol, Propranolol, or CARVEDILOL) |
| to reduce portal inflow; OR Endoscopic Variceal Ligation (EVL). |
| - Acute Variceal Bleed: IV Octreotide bolus + infusion, IV Ceftriaxone |
| prophylaxis x 7 days, restrictive blood transfusion (target Hb 7-8), |
| urgent EGD banding within 12 hours. |
| |
| 4. HEPATIC ENCEPHALOPATHY (HE) |
| - Precipitated by: Constipation, GI bleeding, infection, hypokalemia, |
| dehydration, psychoactive medications. |
| - First-Line Treatment: LACTULOSE (20-30 g oral TID-QID titrated to |
| achieve 2 to 3 soft bowel movements/day; traps NH4+ in stool). |
| - Second-Line / Adjunct: RIFAXIMIN (550 mg orally BID) added for |
| recurrent HE despite lactulose monotherapy. |
| |
| 5. HEPATOCELLULAR CARCINOMA (HCC) SURVEILLANCE |
| - Surveillance Protocol: ABDOMINAL ULTRASOUND +/- SERUM ALPHA- |
| FETOPROTEIN (AFP) EVERY 6 MONTHS for all patients with cirrhosis. |
+-----------------------------------------------------------------------------+
5. Cholelithiasis, Acute Cholecystitis & Biliary Tract Emergencies
Gallstone disease (cholelithiasis) affects 10% to 15% of the adult population. Stones form primarily due to cholesterol supersaturation in bile, gallbladder hypomotility, or accelerated crystallization. Risk factors encompass the classic "5 F's": Female, Forty, Fat (obesity), Fertile (multiparity/estrogen), and Family history.
+-----------------------------------------------------------------------------+
| SPECTRUM OF BILIARY TRACT DISORDERS |
| |
| CONDITION PATHOLOGY CLINICAL SIGNS / LABS |
| ----------------------------------------------------------------------- |
| Biliary Colic Transient cystic duct Colicky RUQ pain lasting 1-5 hr|
| obstruction by stone Postprandial (fatty meals). |
| Normal labs, afebrile. |
| |
| Acute Cholecystitis Sustained cystic duct CONSTANT RUQ pain > 6 hrs, |
| obstruction -> mucosa fever, leukocytosis, POSITIVE |
| inflammation/infection MURPHY'S SIGN. |
| |
| Choledocholithiasis Stone in Common Bile RUQ pain, JAUNDICE, elevated |
| Duct (CBD) direct bilirubin, elevated Alk |
| Phos/GGT, dilated CBD on US. |
| |
| Acute Ascending Bacterial infection CHARCOT'S TRIAD: RUQ Pain + |
| Cholangitis of obstructed biliary Fever/Chills + Jaundice. |
| tree (E. coli, Klebs) REYNOLDS' PENTAD: Charcot's + |
| Hypotension + Mental Confusion |
| (SURGICAL / ERCP EMERGENCY!) |
+-----------------------------------------------------------------------------+
Diagnostic Evaluation & Physical Examination Signs
- Murphy's Sign: Palpate the right upper quadrant below the costal margin and ask the patient to take a deep inspiration. A positive test is the sudden inspiratory arrest due to sharp pain when the inflamed gallbladder descends and contacts the examining fingers.
- Imaging Modality of Choice: Right Upper Quadrant (RUQ) Abdominal Ultrasound (Sensitivity > 90% for stones).
- Ultrasound Findings of Acute Cholecystitis: Gallbladder wall thickening (> 3 mm), pericholecystic fluid halo, gallstones with acoustic shadowing, and a sonographic Murphy's sign.
- HIDA Scan (Cholescintigraphy): The most sensitive and specific diagnostic test for acute cholecystitis when ultrasound is equivocal. Non-visualization of the gallbladder after 1–4 hours indicates complete cystic duct obstruction.
A 56-year-old male with a history of hypertension, obesity (BMI 34.2 kg/m²), and Type 2 Diabetes presents for a routine chronic disease evaluation. Routine laboratory testing reveals: AST 58 U/L, ALT 72 U/L, Total Bilirubin 0.8 mg/dL, Alkaline Phosphatase 88 U/L, and Platelet count 112,000/mm³. An abdominal ultrasound confirms marked diffuse hepatic steatosis without focal masses. Calculating his FIB-4 index yields a score of 3.42. What is the AGPCNP's most appropriate clinical interpretation and next action?
A 42-year-old female presents to establish primary care. As part of a preventive health evaluation, a viral hepatitis screening panel is obtained with the following results: Hepatitis B surface antigen (HBsAg) negative; Hepatitis B surface antibody (Anti-HBs) positive; Hepatitis B core antibody IgM (Anti-HBc IgM) negative; Hepatitis B core antibody total (Anti-HBc Total) positive. How should the AGPCNP interpret these serological findings?
A 62-year-old male with decompensated alcohol-related cirrhosis is admitted to the hospital with worsening abdominal distension, mild abdominal discomfort, and a low-grade temperature of 38.1°C (100.6°F). A diagnostic paracentesis is performed, and peritoneal fluid analysis yields: Total WBC 920/mm³ with 68% polymorphonuclear neutrophils (PMNs), Total Protein 0.9 g/dL, and Albumin 0.4 g/dL. Concurrently drawn serum albumin is 2.2 g/dL. Which of the following represents the correct diagnosis, SAAG calculation, and immediate pharmacological management?